SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Cyclo Therapeutics, Inc. CYTHW NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Cyclo Therapeutics, Inc. (CYTHW) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.03. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $1M, +13.5%/yr average growth. Net income is $20M (loss), growing at -32.8%/yr. Net profit margin is -1863.4% (negative). Gross margin is 90.9% (-1.8 pp trend).

Balance sheet: total debt is $1M against $5M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 1.45 (adequate). Debt-to-assets is 7.8%. Total assets: $13M.

Analyst outlook: 1 / 1 analysts rate CYTHW as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 46/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

CYTHW SharesGrow Score Overview

56/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 48/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 75/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CYTHW

No analyst coverage available for this stock.

CYTHW: +13.5%/yr revenue is, -32.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet CYTHW: Debt-to-Equity (D/E) ratio 0.22 (conservative), Current ratio is 1.45 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CYTHW: Gross margin is 90.9% (-1.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate CYTHW as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CYTHW: Net profit margin is -1863.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.025-0.614

Volume28.41K

Avg Volume (30D)12.32K

Market Cap$899.37K

Beta (1Y)-0.57

Share Statistics

EPS (TTM)-1.23

Shares Outstanding$16.33M

IPO Date2020-12-18

Employees8

CEON. Scott Fine

Financial Highlights & Ratios

Revenue (TTM)$1.08M

Gross Profit$977.95K

EBITDA$-20.03M

Net Income$-20.06M

Operating Income$-20.05M

Total Cash$9.25M

Total Debt$1.03M

Net Debt$-8.21M

Total Assets$13.25M

Price / Earnings (P/E)-0

Price / Sales (P/S)0.84

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS23254X1101

Price Chart

CYTHW

Cyclo Therapeutics, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Drug Manufacturers - Specialty & Generic

0.03 52WK RANGE 0.61

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message